ahlam1399
03-15-2016, 03:00 PM
Orexigen buys U.S. rights to obesity drug from Takeda
(Reuters) - Orexigen Therapeutics Inc said it would pay $60 million to acquire the U.S. rights to its flagship obesity drug from partner Takeda Pharmaceutical Co.
http://rc.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/rc/1/rc.img (http://rc.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/rc/1/rc.htm)
http://rc.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/rc/2/rc.img (http://rc.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/rc/2/rc.htm)
http://rc.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/rc/3/rc.img (http://rc.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/rc/3/rc.htm)
http://da.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/a2.img (http://da.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/a2.htm)
http://adchoice.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/ach.img (http://adchoice.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/ach.htm)http://pi.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/a2t.imghttp://pi2.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/a2t2.imghttp://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e4630ca/sc/19/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=6niIrfCDhTc:1acu3pvKZ2w:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=6niIrfCDhTc:1acu3pvKZ2w:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=6niIrfCDhTc:1acu3pvKZ2w:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=6niIrfCDhTc:1acu3pvKZ2w:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=6niIrfCDhTc:1acu3pvKZ2w:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/6niIrfCDhTc
(Reuters) - Orexigen Therapeutics Inc said it would pay $60 million to acquire the U.S. rights to its flagship obesity drug from partner Takeda Pharmaceutical Co.
http://rc.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/rc/1/rc.img (http://rc.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/rc/1/rc.htm)
http://rc.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/rc/2/rc.img (http://rc.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/rc/2/rc.htm)
http://rc.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/rc/3/rc.img (http://rc.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/rc/3/rc.htm)
http://da.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/a2.img (http://da.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/a2.htm)
http://adchoice.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/ach.img (http://adchoice.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/ach.htm)http://pi.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/a2t.imghttp://pi2.feedsportal.com/r/247394829636/u/49/f/654207/c/35217/s/4e4630ca/sc/19/a2t2.imghttp://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e4630ca/sc/19/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=6niIrfCDhTc:1acu3pvKZ2w:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=6niIrfCDhTc:1acu3pvKZ2w:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=6niIrfCDhTc:1acu3pvKZ2w:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=6niIrfCDhTc:1acu3pvKZ2w:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=6niIrfCDhTc:1acu3pvKZ2w:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/6niIrfCDhTc